Colorectal cancer prevention in ulcerative colitis: a case-control study

Area of Science:

• Gastroenterology
• Oncology
• Clinical Epidemiology

Background:

• Ulcerative colitis (UC) patients face an elevated risk of colorectal cancer (CRC), increasing with disease extent and duration.
• Identifying specific risk factors is crucial for targeted surveillance strategies in UC-associated CRC.
• Cost-effective surveillance requires precise identification of high-risk patient subgroups.

Purpose of the Study:

• To investigate risk factors for colorectal cancer (CRC) in patients with ulcerative colitis (UC).
• To identify modifiable and non-modifiable factors influencing CRC development in UC.
• To inform targeted surveillance protocols for UC patients at high risk of CRC.

Main Methods:

• A case-control study design was employed, comparing 102 CRC cases in UC patients with matched controls.
• Conditional logistic regression was used to estimate odds ratios (OR) for cancer risk.
• A multivariate model was utilized to assess the independent contribution of various risk factors.

Main Results:

• Regular 5-aminosalicylic acid (5-ASA) therapy was associated with a 75% reduction in CRC risk (OR 0.25).
• Mesalazine use showed an 81% risk reduction (OR 0.19), and frequent hospital visits (>twice/year) reduced risk by 84% (OR 0.16).
• A family history of sporadic CRC significantly increased risk fivefold (OR 5.0).

Conclusions:

• Regular 5-ASA medication is effective in reducing CRC risk for UC patients.
• Colonoscopic surveillance should prioritize UC patients with a positive family history of CRC.
• Individuals with allergies preventing 5-ASA use represent another group for intensified surveillance.